Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
出版年份 2015 全文链接
标题
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 14, Issue 7, Pages 487-498
出版商
Springer Nature
发表日期
2015-05-22
DOI
10.1038/nrd4506
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine Administration: Implications for Clinical Therapy
- (2014) Jeffrey S. Miller et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
- (2014) V. Bachanova et al. BLOOD
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action
- (2014) S. Dubois et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: The Metalloproteinase ADAM17/TNF- -Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein
- (2014) P. Boutet et al. JOURNAL OF IMMUNOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
- (2014) Sawa Ito et al. MOLECULAR THERAPY
- IL-12 Directs Further Maturation of Ex Vivo Differentiated NK Cells with Improved Therapeutic Potential
- (2014) Dorit Lehmann et al. PLoS One
- NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
- (2013) R. Romee et al. BLOOD
- CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
- (2013) M. L. Green et al. BLOOD
- Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy
- (2013) Y. Liu et al. CLINICAL CANCER RESEARCH
- Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
- (2013) A. Wiernik et al. CLINICAL CANCER RESEARCH
- Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling
- (2013) Erik Wennerberg et al. INTERNATIONAL JOURNAL OF CANCER
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bringing natural killer cells to the clinic: ex vivo manipulation
- (2013) R. W. Childs et al. Hematology-American Society of Hematology Education Program
- Therapeutic applications: natural killer cells in the clinic
- (2013) J. S. Miller Hematology-American Society of Hematology Education Program
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
- (2013) A. W. MacFarlane et al. Cancer Immunology Research
- Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7
- (2012) S. S. Somanchi et al. BLOOD
- Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
- (2012) Heather E. Eve et al. BRITISH JOURNAL OF HAEMATOLOGY
- Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
- (2012) Natalia Lapteva et al. CYTOTHERAPY
- A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies
- (2012) Noriko Shimasaki et al. CYTOTHERAPY
- Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
- (2012) Christine Wolschke et al. EXPERIMENTAL HEMATOLOGY
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- (2012) T. K. Garg et al. HAEMATOLOGICA
- Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
- (2012) Nidale Tarek et al. JOURNAL OF CLINICAL INVESTIGATION
- Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen
- (2012) B. Foley et al. JOURNAL OF IMMUNOLOGY
- Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
- (2012) M. K. Gleason et al. MOLECULAR CANCER THERAPEUTICS
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Anti-CD20 Antibody Therapy for B-Cell Lymphomas
- (2012) David G. Maloney NEW ENGLAND JOURNAL OF MEDICINE
- Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
- (2012) Cecele J. Denman et al. PLoS One
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients
- (2011) A. H. Elmaagacli et al. BLOOD
- Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
- (2011) B. Foley et al. BLOOD
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
- (2011) D. M. Benson et al. BLOOD
- Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
- (2011) Asher A. Chanan-Khan et al. BRITISH JOURNAL OF HAEMATOLOGY
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD
- (2011) Silke Wiesmayr et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes
- (2011) Anne-Hélène Pillet et al. HUMAN IMMUNOLOGY
- Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells
- (2011) M. Enqvist et al. JOURNAL OF IMMUNOLOGY
- Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells
- (2011) Hua Zhang et al. JOURNAL OF IMMUNOTHERAPY
- Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
- (2011) S. Lopez-Verges et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interleukin-15 biology and its therapeutic implications in cancer
- (2011) Jason C. Steel et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer
- (2010) Jan Pander et al. EUROPEAN JOURNAL OF CANCER
- Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
- (2010) Stacey L. Berg et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-15R -IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor Action through NK and CD8+ T Cells Proliferation and Activation
- (2010) Z. Wu et al. Journal of Molecular Cell Biology
- Safety and immunologic effects of IL-15 administration in nonhuman primates
- (2009) C. Berger et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
- (2009) A. Lundqvist et al. BLOOD
- Replicative potential of human natural killer cells
- (2009) Hiroyuki Fujisaki et al. BRITISH JOURNAL OF HAEMATOLOGY
- Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
- (2009) L Li et al. CANCER GENE THERAPY
- Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
- (2009) Maria Berg et al. CYTOTHERAPY
- In vivotumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL-2
- (2009) Gustaf Vahlne et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Interleukin-12 Receptor β2: From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies
- (2009) Vito Pistoia et al. JOURNAL OF CLINICAL ONCOLOGY
- A Programmed Switch from IL-15- to IL-2-Dependent Activation in Human NK Cells
- (2009) Anne-Hélène Pillet et al. JOURNAL OF IMMUNOLOGY
- Differential Effects of Selenium on Benign and Malignant Prostate Epithelial Cells: Stimulation of LNCaP Cell Growth by Noncytotoxic, Low Selenite Concentrations
- (2009) Nur Özten Kandaş et al. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
- Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
- (2009) C. Sola et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
- (2008) Jumei Shi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
- (2008) Dan Zhu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors
- (2008) M. Vales-Gomez et al. CANCER RESEARCH
- Line of attack: NK cell specificity and integration of signals
- (2008) Yenan T Bryceson et al. CURRENT OPINION IN IMMUNOLOGY
- Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice
- (2008) Lena A Basile et al. Journal of Translational Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now